Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDQuarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
---|---|---|---|---|
Q1 2024 | 1 | -$0.13 | -$0.13 | -$0.13 |
Q2 2024 | 3 | -$0.14 | -$0.10 | -$0.12 |
Q3 2024 | 1 | -$0.08 | -$0.08 | -$0.08 |
Q1 2025 | 1 | -$0.08 | -$0.08 | -$0.08 |
Q2 2025 | 1 | -$0.08 | -$0.08 | -$0.08 |
Q3 2025 | 1 | -$0.08 | -$0.08 | -$0.08 |
Lexaria Bioscience Corp. last posted its earnings results on Tuesday, November 26th, 2024. The company reported $-0.15 earnings per share for the quarter, missing analysts' consensus estimates of $-0.11 by $0.04. The company had revenue of 84,000 for the quarter and had revenue of 464,278 for the year. Lexaria Bioscience Corp. has generated $0 earnings per share over the last year ($-0.47 diluted earnings per share) and currently has a price-to-earnings ratio of -4.44. Lexaria Bioscience Corp. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Friday, January 10th, 2025 based on prior year's report dates.
Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
---|---|---|---|---|---|---|
11/26/2024 | Q4 2024 | -$0.11 | $0.00 | $200,000 | $84,000 | |
07/12/2024 | Q3 2024 | -$0.09 | -$0.13 | -0.04 | $106,000 | $84,000 |
04/09/2024 | Q2 2024 | -$0.10 | -$0.06 | 0.04 | $145,000 | |
01/12/2024 | Q1 2024 | -$0.11 | -$0.13 | -0.02 | $151,278 | |
11/20/2023 | Q4 2023 | -$0.19 | $10,000 | $-3,433 | ||
07/14/2023 | Q3 2023 | -$0.25 | -$0.37 | -0.12 | $93,150 | |
04/14/2023 | Q2 2023 | -$0.22 | $35,015 | |||
01/18/2023 | Q1 2023 | -$0.30 | $101,476 | |||
11/25/2022 | Q4 2022 | -$0.25 | $120,000 | $111,150 | ||
07/14/2022 | Q3 2022 | -$0.28 | -$0.40 | -0.12 | $150,000 | $99,717 |
04/11/2022 | Q2 2022 | -$0.21 | -$0.24 | -0.03 | $30,650 | |
01/14/2022 | Q1 2022 | -$0.35 | $13,880 | |||
11/26/2021 | Q4 2021 | -$0.23 | -$0.23 | 0 | $31,021 | |
07/15/2021 | Q3 2021 | -$0.50 | $204,055 | |||
04/14/2021 | Q2 2021 | $0.09 | $192,006 | |||
01/14/2021 | Q1 2021 | -$0.23 | $295,656 | |||
10/14/2020 | Q4 2020 | -$0.14 | $133,739 | |||
06/30/2020 | Q3 2020 | -$0.49 | $81,423 | |||
04/02/2020 | Q2 2020 | -$0.36 | $107,299 | |||
01/08/2020 | Q1 2020 | -$0.34 | $62,082 |
Lexaria Bioscience Corp. has not confirmed its next earnings publication date, but the company's estimated earnings date is Friday, January 10th, 2025 based off last year's report dates.
The conference call for Lexaria Bioscience Corp.'s latest earnings report can be listened to online.
The conference call transcript for Lexaria Bioscience Corp.'s latest earnings report can be read online.
Lexaria Bioscience Corp. (:LEXX) has a recorded annual revenue of $464,278.
Lexaria Bioscience Corp. (:LEXX) has a recorded net income of $464,278. Lexaria Bioscience Corp. has generated $-0.47 earnings per share over the last four quarters.
Lexaria Bioscience Corp. (:LEXX) has a price-to-earnings ratio of -4.44 and price/earnings-to-growth ratio is -0.12.
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTED